A novel proteomics-based approach to find more accurate biomarkers for mesothelioma.

Malignant pleural mesothelioma (MPM) is a cancer caused by long-term exposure to asbestos. MPM is very aggressive with poor prognosis. Currently, high levels of mesothelin in blood, in combination with other invasive tests, help to diagnose MPM, but mesothelin levels do not suffice by themselves as correct diagnostic biomarkers. Here, we aim at performing a proteomic study on blood plasma samples from MPM patients which combines for the first time two approaches being selection of low abundant proteins originating from cancer cells (tissue leakage proteins), and sensitive mass spectrometrybased analysis, recently successfully introduced in clinical proteomics. Our workflow is based on dedicated protein selection and overall analytical sensitivity, both that are currently missing in blood biomarkers studies.

Keywords:PROTEOMICS, CANCER BIOMERKERS, ASBESTES (IN AIR,WATER, SOIL), MALIGNANT MESOTHELIOMA

Disciplines:Protein diagnostics, Cancer diagnosis, Respiratory medicine

Project type:Collaboration project